Breaking News Instant updates and real-time market news.

NXTC

NextCure

$52.29

-4.27 (-7.55%)

, LLY

Eli Lilly

$139.02

1.01 (0.73%)

15:27
01/13/20
01/13
15:27
01/13/20
15:27

NextCure reports Lilly's termination of R&D collaboration agreement

In a regulatory filing earlier, NextCure (NXTC) reported that on January 10, Eli Lilly (LLY) notified the company of Lilly's termination, effective as of March 3, 2020, of the research and development collaboration agreement, dated as of November 2, 2018, between the company and Lilly.

NXTC

NextCure

$52.29

-4.27 (-7.55%)

LLY

Eli Lilly

$139.02

1.01 (0.73%)

  • 13

    Jan

  • 27

    Jan

  • 30

    Jan

  • 10

    Feb

NXTC NextCure
$52.29

-4.27 (-7.55%)

12/05/19
NEED
12/05/19
INITIATION
Target $72
NEED
Buy
NextCure initiated with a Buy at Needham
Needham analyst Chad Messer initiated coverage of NextCure with a Buy rating and $72 price target. The company's "validated" technology could represent the next big breakthrough in immuno-oncology, Messer tells investors in a research note. He believes targeting S15 holds the promise of providing benefit to patients who have failed PD-1/PD-L1 blockade. NextCure's lead asset has already achieved human proof-of-concept as a monotherapy in PD-1/PD-L1 inhibitor refractory patients, contends the analyst.
01/06/20
PIPR
01/06/20
NO CHANGE
PIPR
Overweight
NextCure named a top pick for 2020 at Piper Sandler
Piper Sandler analyst Edward Tenthoff named NextCure a top pick for 2020 and reiterates an Overweight rating on the shares with an $87 price target. The analyst expects additional NC318 data this year and says the Phase I data presented at SITC demonstrated clear monotherapy activity.
01/13/20
RHCO
01/13/20
INITIATION
Target $78
RHCO
Buy
NextCure initiated with a Buy at SunTrust
SunTrust analyst Asthika Goonewardene initiated coverage of NextCure with a Buy rating and $78 price target. The analyst cites the potential of the company's lead asset NC318 in immuno-oncology, saying the first data for the program is "reminiscent" of IO's early days. Goonewardene further notes that the "gradual creep" in NextCure is indicative of new investors digesting its investment story and getting into the stock showing positive momentum.
01/13/20
PIPR
01/13/20
NO CHANGE
Target $87
PIPR
Overweight
Partnership termination not a negative for NextCure N318, says Piper Sandler
Piper Sandler analyst Edward Tenthoff notes that NextCure (NXTC) disclosed that Eli Lilly (LLY) is terminating an I-O discovery alliance based on the former's FIND-IO platform effective March 3rd. The analyst does not view this termination as a negative for NextCure's existing, wholly-owned antibodies NC318 and NC410 and is a buyer on weakness. Tenthoff adds that NextCure remains a top pick for 2020 ahead of additional NC318 data this year. He reiterates an Overweight rating and $87 price target on NextCure's shares.
LLY Eli Lilly
$139.02

1.01 (0.73%)

12/20/19
STFL
12/20/19
NO CHANGE
STFL
Hold
Stifel says Lexicon 'missed opportunity' with sotagliflozin data
After Lexicon Pharmaceutical (LXRX) announced earlier that sotagliflozin 400 mg achieved the primary endpoint of superiority on A1C reduction versus placebo in the Phase 3 SOTA-EMPA study in type 2 diabetes, Stifel analyst Stephen Willey said he views the inability of sotagliflozin to demonstrate statistically superior HbA1c reduction versus Eli Lilly's (LLY) empagliflozin as a "relative disappointment" and "missed opportunity." The analyst, who had seen this trial as "the best remaining opportunity to establish commercial differentiation" in type 2 diabetes in a crowded field of selective SGLT2i drugs, keeps a Hold rating on Lexicon shares.
12/30/19
ARGS
12/30/19
NO CHANGE
Target $165
ARGS
Buy
Eli Lilly price target raised to $165 from $145 at Argus
Argus analyst David Toung raised his price target on Eli Lilly to $165 and kept his Buy rating, noting the company's FY20 earnings guidance issued earlier this month was stronger than he expected. The analyst also anticipates increased volume and expanded indications for the company's existing drugs supporting its earnings. Toung further cites 2020 benefits for Eli Lilly that include Q3's commercial and regulatory developments such as FDA approval of Reyvow, the additional FDA indication for Taltz, and European Commission's approved update for Trulicity.
01/08/20
PIPR
01/08/20
NO CHANGE
PIPR
Neutral
Eli Lilly still has edge over Blueprint in RET+ lung cancer, says Piper Sandler
After Blueprint Medicines (BPMC) disclosed about 7 months of additional data from the P1/2 ARROW study in patients with RET fusion-positive non-small cell lung cancer, or NSCLC, Piper Sandler analyst Christopher Raymond noted that mDOR was not reached and that CNS response data were not provided. With pralsetinib's durability still not known, he continues to believe Eli Lilly (LLY) "has the edge" in treating later-line NSCLC patients with selpercatinib. Raymond, who prefers "to watch this story play out from the sidelines," maintains a Neutral rating on Blueprint shares.

TODAY'S FREE FLY STORIES

SMUUY

Siam Commercial Bank

$0.00

(0.00%)

13:37
01/20/20
01/20
13:37
01/20/20
13:37
Downgrade
Siam Commercial Bank rating change  »

Siam Commercial Bank…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SMUUY

Siam Commercial Bank

$0.00

(0.00%)

13:37
01/20/20
01/20
13:37
01/20/20
13:37
Downgrade
Siam Commercial Bank rating change  »

Siam Commercial Bank…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNVVY

ConvaTec

$0.00

(0.00%)

13:35
01/20/20
01/20
13:35
01/20/20
13:35
Downgrade
ConvaTec rating change  »

ConvaTec downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:35
01/20/20
01/20
13:35
01/20/20
13:35
General news
FX Summary: Activity was moribund »

FX Summary: Activity was…

KSU

Kansas City Southern

$166.57

4.77 (2.95%)

13:31
01/20/20
01/20
13:31
01/20/20
13:31
Recommendations
Kansas City Southern analyst commentary  »

Kansas City Southern…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRM

Salesforce

$182.16

-0.53 (-0.29%)

13:06
01/20/20
01/20
13:06
01/20/20
13:06
Recommendations
BMO keeps 'top pick' status on Salesforce, boosts price target to $210 »

BMO Capital analyst Keith…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Mar

SNYYF

Sany Heavy

$0.00

(0.00%)

12:56
01/20/20
01/20
12:56
01/20/20
12:56
Upgrade
Sany Heavy rating change  »

Sany Heavy upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATDRY

Auto Trader Group

$0.00

(0.00%)

12:52
01/20/20
01/20
12:52
01/20/20
12:52
Upgrade
Auto Trader Group rating change  »

Auto Trader Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIOSF

Atresmedia

$0.00

(0.00%)

12:50
01/20/20
01/20
12:50
01/20/20
12:50
Downgrade
Atresmedia rating change  »

Atresmedia downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LGDDF

Lagardere

$0.00

(0.00%)

12:48
01/20/20
01/20
12:48
01/20/20
12:48
Downgrade
Lagardere rating change  »

Lagardere downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WPP

WPP

$66.38

-0.34 (-0.51%)

12:47
01/20/20
01/20
12:47
01/20/20
12:47
Downgrade
WPP rating change  »

WPP downgraded to Neutral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WTKWY

Wolters Kluwer

$0.00

(0.00%)

12:46
01/20/20
01/20
12:46
01/20/20
12:46
Downgrade
Wolters Kluwer rating change  »

Wolters Kluwer downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CIOXY

Cielo

$0.00

(0.00%)

12:43
01/20/20
01/20
12:43
01/20/20
12:43
Downgrade
Cielo rating change  »

Cielo downgraded to Sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

10:35
01/20/20
01/20
10:35
01/20/20
10:35
General news
Taking an "irrationally bullish" view of U.S. and global stock markets »

Taking an…

09:30
01/20/20
01/20
09:30
01/20/20
09:30
General news
Oil Action: Front-month WTI futures are up 0.7% »

Oil Action: Front-month…

07:00
01/20/20
01/20
07:00
01/20/20
07:00
General news
FX Update: All quiet on the forex front »

FX Update: All quiet on…

06:40
01/20/20
01/20
06:40
01/20/20
06:40
General news
FX Action: USD-JPY has gone into narrow-range mode »

FX Action: USD-JPY has…

HRB

H&R Block

$24.48

-0.48 (-1.92%)

04:55
01/20/20
01/20
04:55
01/20/20
04:55
Conference/Events
H&R Block management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jan

  • 21

    Jan

  • 22

    Jan

AMRC

Ameresco

$19.78

-0.1 (-0.50%)

04:55
01/20/20
01/20
04:55
01/20/20
04:55
Conference/Events
Ameresco management to meet with Roth Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jan

  • 21

    Jan

  • 22

    Jan

MSM

MSC Industrial

$76.89

-1.58 (-2.01%)

04:55
01/20/20
01/20
04:55
01/20/20
04:55
Conference/Events
MSC Industrial management to meet with KeyBanc »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jan

  • 29

    Jan

03:30
01/20/20
01/20
03:30
01/20/20
03:30
General news
FX Action: USD-CAD ebbed fractionally lower »

FX Action: USD-CAD ebbed…

03:05
01/20/20
01/20
03:05
01/20/20
03:05
General news
Asian Market Update: »

Asian Market Update:…

03:05
01/20/20
01/20
03:05
01/20/20
03:05
General news
FX Update: The dollar has seen modest weakness »

FX Update: The dollar has…

FB

Facebook

$222.01

0.23 (0.10%)

16:50
01/19/20
01/19
16:50
01/19/20
16:50
Periodicals
Facebook blames technical error for vulgar translation, Reuters reports »

Facebook blamed a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 29

    Jan

SPY

SPDR S&P 500 ETF Trust

$331.98

1.08 (0.33%)

, SPX

S&P 500

$0.00

(0.00%)

16:43
01/19/20
01/19
16:43
01/19/20
16:43
Periodicals
China to increase U.S. imports according to 'market principles,' Reuters reports »

China will negotiate with…

SPY

SPDR S&P 500 ETF Trust

$331.98

1.08 (0.33%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.